Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025

Aptevo Therapeutics Inc.

Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.
Presentation will highlight ADAPTIR platform using clinical candidates Mipletamig and ALG.APV-527 as proof of concept.
Aptevo has five compounds in clinical/preclinical development and plans a new molecule in early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.